ArticleFrontiers in pharmacology2026
Xinnaoxin tablets ameliorate high-altitude polycythemia-associated cardiac injury by regulating the NF-κB, MAPK, and PI3K/AKT signaling pathways.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: High-altitude polycythemia (HAPC) and its associated cardiac complications, induced by hypobaric hypoxia (HH), pose significant clinical challenges. Xinnaoxin (XNX) tablets are clinically utilized for these conditions; however, their integrated multi-target mechanisms remain poorly understood. This study aims to elucidate the novel mechanisms and therapeutic potential of XNX against HAPC and HH-induced cardiac injury. For the first time, we employed a combined strategy of systems pharmacology and multi-level analysis to comprehensively investigate how XNX confers synergistic protection by modulating both the hematopoietic microenvironment and myocardial signaling networks. Methods: The metabolites of XNX were systematically identified, and its chemical profile was established using UPLC-Q-TOF-MS. An HH mouse model was generated by simulating a high-altitude hypoxic environment. Comprehensive assessments included complete blood parameters, hemorheology, the proportion and apoptosis of CD71 Results: XNX significantly reversed HH-induced elevations in red blood cell count, hemoglobin, hematocrit, white blood cell count, and plasma viscosity, while reducing serum EPO levels. Notably, XNX decreased the bone marrow population of CD71 Conclusion: XNX exerts its therapeutic effects through a dual mechanism: (1) ameliorating HAPC at its source by regulating EPO expression and enhancing bone marrow erythropoietic efficiency, and (2) counteracting HH-induced cardiac injury via multi-target modulation of the MAPK-related signaling network. These findings clarify the pharmacological basis of XNX and provide a theoretical foundation for developing multi-pathway synergistic therapies for high-altitude hypoxia-related cardiovascular diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.